This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Nearly half of the study population comprised of high-risk/immunocompromised patients. The high-risk patients included those with chronic medical conditions such as congestive heart failure, chronic obstructive pulmonary disease and diabetes mellitus. Therefore, the study confirmed the effectiveness of PCV13 in patients with VT-CAP who belonged to high-risk or immunocompromised groups of elderly population1
The 73% VE against 3.7% of CAP in the study can be translated to an estimated rate of 62 per 100,000 person-years reduction of hospitalised CAP1
The study highlighted the substantial benefits of continued PCV13 vaccination in the US and global adult population1
One of the reasons for licensing PCV13 in adults was to address the limitations of previous plain polysaccharide vaccines and the unmet medical need of VT-CAP. Although clinical effectiveness studies have been performed with PPSV23 to assess their ability to adequately prevent non-bacteraemic pneumococcal pneumonia in older adults, such results are inconsistent. In this context, the CAPiTA study demonstrated PCV13 efficacy against both CAP and non-bacteraemic VT-CAP, thereby indicating the meaningful therapeutic benefit of PCV13 over other existing treatments2
The CAPiTA study demonstrated the efficacy of PCV13 against overall and non-bacteraemic VT-CAP in older adults, aged ≥65 years, excluding the high-risk group of patients. The present study complemented the findings of the CAPiTA study by assessing the real-world effectiveness of PCV13 vaccination after introduction into the adult US population following the ACIP 2014 recommendations. The study also assessed VE in high-risk elderly patients1
ACIP, Advisory Committee on Immunization Practices; CAP, community-acquired pneumonia; CAPiTA, Community-Acquired Pneumonia Immunization Trial in Adults; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine; VE, vaccine effectiveness; VT-CAP, vaccine-type community-acquired pneumonia.
References:
McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498-1506.
McLaughlin JM, Swerdlow DL, Isturiz RE, Jodar L. Decision-making for PCV in adults. Hum Vaccin Immunother. 2019;15(3):584-593.
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0661 July 2023
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.